Hepatitis C and Injecting Drug Use
Hepatitis C and Injecting Drug UseEuropean Monitoring Centre for Drugs and Drug Addiction
Sign up to use
Hepatitis C and Injecting Drug Use

Hepatitis C and Injecting Drug Use Impact, Costs and Policy Options

Sign up to use
Sign up to use
Established in 1993, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is an EU agency which collects and disseminates comparable evidence-based data on drugs and drug addiction in Europe. This publication is the seventh in the series of scientific monographs and contains papers on the topic of hepatitis C and injecting drug users. It is divided into four parts dealing with: natural history, treatment, quality of life, epidemiology and prevention issues; models of hepatitis C infection, injecting drug use and policy options; healthcare costs and wider costs of drug use; cost-effectiveness of needle and syringe programmes and methadone maintenance.